文献速递细菌感染、耐药与抗菌药物

胃癌患者幽门螺杆菌临床分离株的抗菌药物耐药模式

Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients.
PubMed 文献 · J Infect Dis · 2025-01-01

研究纳入115例计划胃切除的胃癌患者,从胃黏膜样本培养出86株幽门螺杆菌(培养率74.8%)。药敏显示对利福平、甲硝唑、克拉霉素和左氧氟沙星耐药率较高,对阿莫西林、四环素和呋喃唑酮耐药率低。提示胃癌术后残留胃黏膜的根除治疗可考虑以阿莫西林和/或米诺环素为基础的方案。

要点

  • 胃癌患者幽门螺杆菌对利福平、甲硝唑、克拉霉素和左氧氟沙星耐药率高。
  • 对阿莫西林、四环素和呋喃唑酮耐药率低,可作为根除方案选择。
  • 远端胃切除后残留胃黏膜者,可考虑阿莫西林和/或米诺环素为基础方案。

核心结论

  • 胃癌患者幽门螺杆菌分离株对利福平、甲硝唑、克拉霉素和左氧氟沙星呈现高耐药,对阿莫西林、呋喃唑酮和四环素耐药率极低。

研究设计与样本

  • 研究连续纳入115例13C尿素呼气试验阳性、计划在四川大学华西医院行胃切除的胃癌患者,采集胃黏膜行病理检查、幽门螺杆菌培养及药敏试验(E-test和纸片扩散法)。

主要发现

  • 从115份标本中培养出86株幽门螺杆菌,培养率74.8%。
  • 86例成功分离幽门螺杆菌的患者中,男59例、女27例,中位年龄59岁(范围34-79岁)。
  • 组织病理学显示肠型37例、弥漫型27例、混合型9例、未分类13例。
  • 12例年龄≤45岁,其中9例女性,均为印戒细胞癌。

关键数值与推荐

  • 药敏耐药率:利福平69.8%、甲硝唑75.6%、克拉霉素41.9%、左氧氟沙星32.6%、阿莫西林2.3%、四环素1.2%、呋喃唑酮0%。

临床怎么用

  • 对于远端胃切除术后残留胃黏膜的胃癌患者,可考虑以阿莫西林和/或米诺环素为基础的幽门螺杆菌根除方案,以降低异时性胃癌风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The increasing antibiotic resistance of Helicobacter pylori poses challenges in selecting effective eradication therapies for patients with gastric cancer. This study aimed to assess the antibiotic resistance patterns of clinical H. pylori strains isolated from gastric cancer patients, to guide H. pylori eradication strategies for those with residual gastric mucosa after gastrectomy. METHODS: This study enrolled 115 consecutive patients with gastric cancer who had a positive 13C urea breath test, all of whom were scheduled for gastric resection at West China Hospital of Sichuan University. Gastric mucosa samples were collected for pathological examination, H. pylori culture, and susceptibility testing using E-test and disk diffusion methods. RESULTS: From 115 specimens, 86 H. pylori strains were cultured (74.8% culture rate). Of the 86 patients (59 males, 27 females; median age 59, range 34-79) with successful H. pylori isolation, histopathology revealed 37 intestinal-type, 27 diffuse-type, 9 mixed-type, and 13 unclassified gastric cancers. Sixty-one patients underwent distal gastrectomy, and 25 had radical total gastrectomy. Notably, 12 patients were diagnosed at ≤45 years, including 9 females, all with signet ring cell carcinoma. Antibiotic resistance rates were rifampicin (RIF) (69.8%), metronidazole (MTZ) (75.6%), clarithromycin (CLR) (41.9%), levofloxacin (LEV) (32.6%), amoxicillin (AML) (2.3%), tetracycline (TET) (1.2%), and furazolidone (FZD) (0%). CONCLUSIONS: H. pylori isolates from gastric cancer patients exhibited high resistance to RIF, MTZ, CLR, and LEV, but negligible resistance to AML, FZD, and TET. Given the compromised health status and need for concurrent therapies in these patients, AML- and/or minocycline-based regimens may represent a practical and effective treatment option for H. pylori eradication in gastric cancer patients with residual gastric mucosa after distal gastrectomy, to reduce the risk of metachronous gastric cancer.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Liu K, Song X, et al. Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients. J Infect Dis. 2025. PMID: 41264389. doi:10.1093/infdis/jiaf400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。